The move is a reversal from last year, when CVS struck a deal to make Novo's competing GLP-1 drug Wegovy (semaglutide) the preferred obesity treatment on its standard formularies, while excluding Zepbound
United States (National)
Anna Bratulic
Geo Focus
Coverage Attributes:
Beta
Informative:
53
%
Data Driven:
44
%
Interviews Q&as:
1
%
Themes Covered:
Not enough data
Pitching Insights
Anna's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly drug development, clinical trials, and FDA approvals. Her articles heavily feature press releases and cited data.
Given Anna’s focus on private sector announcements and reliance on data, she is likely to be responsive to pitches offering insights from professionals within the pharmaceutical industry who can provide in-depth analysis of new drugs or treatments. Pitches should highlight concrete data or exclusive details related to drug development processes, clinical trial results, or regulatory approvals.
While no specific geographic focus is mentioned for Anna's reporting, her topics cover international pharmaceutical developments rather than a localized perspective.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
